Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate is used for treating HIV-1 infection in pediatric patients weighing at least 35kg without prior antiretroviral treatment or replacing current regimen in virologically suppressed patients. It was first introduced by Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc in its drug Delstrigo on Aug 30, 2018.

Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate Patents

Given below is the list of patents protecting Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Delstrigo	US10603282	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	Nov 29, 2036	Msd Merck Co
Delstrigo	US10842751	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	Nov 29, 2036	Msd Merck Co
Delstrigo	US8486975	Non-nucleoside reverse transcriptase inhibitors	Oct 07, 2031	Msd Merck Co

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳